论文部分内容阅读
目的探讨拉米夫定对乙肝肝硬化患者血清甲状腺激素水平的影响。方法 79例HBV DNA阳性乙肝肝硬化患者接受拉米夫定治疗52周,治疗前后检测血清T3、T4、FT3、FT4、TSH。结果拉米夫定治疗52周后HBV DNA转阴组血清T3、T4、FT3、FT4水平较治疗前和HBV DNA未转阴组均有明显改善(P<0.05)。结论乙肝肝硬化患者在拉米夫定抗乙肝病毒取得较好疗效的同时可以显著改善血清甲状腺激素水平。
Objective To investigate the effect of lamivudine on serum thyroid hormone in patients with hepatitis B cirrhosis. Methods Serum T3, T4, FT3, FT4 and TSH were detected in 79 patients with HBV DNA positive hepatitis B cirrhosis after 52 weeks of lamivudine treatment. Results After 52 weeks of lamivudine treatment, serum T3, T4, FT3 and FT4 levels in patients with HBV DNA negative conversion were significantly improved (P <0.05) compared with before treatment and HBV DNA non-negative patients. Conclusions Patients with hepatitis B cirrhosis can achieve a significant improvement of serum thyroid hormone level while achieving better therapeutic effect of hepatitis B virus infection by lamivudine.